In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Sales & Earnings Manufacturing United States

Price Rises Return Akorn To Sales Growth

Continuing To Work Through Facility Compliance Issues

  • News

Executive Summary

Raising prices for certain product lines helped Akorn to post its first sales growth since 2016 as the US injectables and ophthalmics firm worked towards addressing two FDA warning letters.

You may also be interested in...



Akorn Considers Bankruptcy Filing

Buried within its financial disclosure of a standstill agreement with creditors until 7 February, Akorn disclosed that it is considering whether to file for bankruptcy protection in the US.

Akorn Receives Second Warning Letter In Six Months

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Table

View full table

Topics

Related Companies

Tags:
Sales & Earnings Manufacturing United States
Latest Headlines

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

Six New Molecules By 2030 – J&J’s Neuroscience Strategy

China VBP, Localization And Other Strategies - How Far And Which Way?

See All
UsernamePublicRestriction

Register

GB149321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By